Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MTPC, Daiichi Sankyo to Launch DPP-4 Inhibitor Tenelia on Sept. 10
August 29, 2012
- Izumo, Former VP of Novartis Institutes for BioMedical Research, Appointed Head of Takeda’s MD Drug Discovery Unit
August 29, 2012
- JT’s Licensee Obtains US Approval for Combination Tablet Containing JTK-303
August 29, 2012
- Nichi-Iko Voluntarily Recalls Lansoprazole OD Tablets 15 mg
August 29, 2012
- Daiichi Sankyo, Eli Lilly Not to Apply for Prasugrel for ACS in the US, Europe
August 29, 2012
- Major US, European Pharmaceutical Makers Faced with “Patent Cliffs”
August 28, 2012
- Plavix Approved for STEMI: sanofi-aventis
August 28, 2012
- Strattera Approved as 1st Adult ADHD Treatment in Japan: Eli Lilly Japan
August 28, 2012
- Growject Approved for SGA Dwarfism: JCR
August 28, 2012
- Large Portfolio, Competitive Prices, High Quality to Be Key to Success in Generics Business: Mr Bourla of Pfizer
August 27, 2012
- Japanese Ethical Drug Market Expands by 2.1% in Apr-Jun 2012: IMS Japan
August 27, 2012
- Diovan Approved for Pediatric Hypertension; Japan’s 1st ARB Approved for Pediatric Indication: Novartis
August 27, 2012
- Kyowa Kirin Initiates PII trial of Mogamulizumab in Europe, the US
August 27, 2012
- Once-Daily Administration of Pentasa in Remission Phase Approved; Kyorin Pharmaceutical
August 27, 2012
- Deal with Mylan to Boost Pfizer’s Generic Lineup in Japan with Definite Impact on Competitors
August 27, 2012
- Kyowa Kirin, Otsuka Still Working Out Specifics for Cooperation in Field of Oncology
August 27, 2012
- Forest HD Considering Joint Venture in Indonesia
August 24, 2012
- Pfizer, Mylan Ink Strategic Collaboration in Japan Generics Biz; Aim for No. 3 in Market
August 24, 2012
- Azilva Ranked No. 1 for Third Consecutive Month in Both GP, HP Markets in July: Rep Track Survey
August 23, 2012
- Janssen Pharmaceutical Appoints Goodwin as Next President
August 23, 2012
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…